See more : NZME Limited (NZM.NZ) Income Statement Analysis – Financial Results
Complete financial analysis of YanAn Bicon Pharmaceutical Listed Company (002411.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of YanAn Bicon Pharmaceutical Listed Company, a leading company in the Chemicals industry within the Basic Materials sector.
- Edelweiss Financial Services Limited (EDELWEISS.NS) Income Statement Analysis – Financial Results
- Prism Software Corporation (PSWR) Income Statement Analysis – Financial Results
- Mind Medicine (MindMed) Inc. (MMCWF) Income Statement Analysis – Financial Results
- Al Gassim Investment Holding Company (6020.SR) Income Statement Analysis – Financial Results
- STWC Holdings, Inc. (STWC) Income Statement Analysis – Financial Results
YanAn Bicon Pharmaceutical Listed Company (002411.SZ)
About YanAn Bicon Pharmaceutical Listed Company
YanAn Bicon Pharmaceutical Listed Company researches and develops, produces, and sells pharmaceutical intermediates, pesticide intermediates, and new energy and materials products in China. It offers medical products under the Bikangweizheng and DoctorBaby brands. The company also provides lithium hexafluorophosphate, a material of lithium-ion battery electrolytes for use in cut-resistant gloves, home textile products, cables, fishing nets, outdoor sports wear products, bulletproof helmets, stab-resistant clothing, etc., as well as military industry, aerospace composite materials, ocean-going ships, naval ship ropes, ocean fishing trawls, deep-sea anti-wind wave cages and sporting goods equipment, construction engineering reinforcement, and other high-performance composite materials. In addition, it offers pharmaceutical intermediates, such as triclopyridine sodium, 5,5-dimethylhydantoin, and benzaldehyde. The company was formerly known as JiangSu Bicon Pharmaceutical Listed Company and changed its name to YanAn Bicon Pharmaceutical Listed Company in October 2018. YanAn Bicon Pharmaceutical Listed Company was founded in 2007 and is based in Xi'an, China. YanAn Bicon Pharmaceutical Listed Company was a former subsidiary of Xinyi Bicon New Medicine Industry Complex Investment Co., Ltd.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.11B | 7.66B | 6.94B | 9.33B | 8.45B | 5.37B | 3.72B | 2.02B | 1.06B | 894.69M | 1.01B | 1.05B | 914.18M | 678.21M | 731.87M | 445.13M | 319.21M |
| Cost of Revenue | 6.08B | 5.31B | 5.61B | 7.27B | 6.30B | 3.50B | 1.68B | 780.10M | 873.75M | 732.45M | 828.09M | 866.26M | 767.44M | 569.47M | 602.52M | 371.88M | 271.92M |
| Gross Profit | 2.03B | 2.35B | 1.33B | 2.06B | 2.14B | 1.87B | 2.04B | 1.24B | 186.52M | 162.24M | 181.68M | 182.75M | 146.74M | 108.75M | 129.35M | 73.25M | 47.29M |
| Gross Profit Ratio | 25.06% | 30.68% | 19.11% | 22.05% | 25.39% | 34.81% | 54.79% | 61.45% | 17.59% | 18.13% | 17.99% | 17.42% | 16.05% | 16.03% | 17.67% | 16.46% | 14.82% |
| Research & Development | 147.47M | 131.54M | 112.31M | 83.63M | 114.80M | 140.98M | 127.65M | 20.72M | 40.00M | 47.66M | 34.50M | 30.02M | 13.93M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 135.39M | 160.76M | 127.85M | 109.39M | 110.41M | 73.61M | 55.75M | 42.10M | 7.78M | 14.03M | 15.74M | 10.57M | 17.70M | 35.74M | 34.87M | 17.45M | 16.03M |
| Selling & Marketing | 279.09M | 239.34M | 399.59M | 476.36M | 449.82M | 393.05M | 479.44M | 348.90M | 33.00M | 26.74M | 24.32M | 20.76M | 19.71M | 15.40M | 16.02M | 11.84M | 9.18M |
| SG&A | 414.49M | 400.10M | 527.44M | 585.74M | 560.23M | 466.66M | 535.19M | 391.00M | 40.78M | 40.76M | 40.06M | 31.33M | 37.41M | 51.14M | 50.88M | 29.29M | 25.21M |
| Other Expenses | 1.16B | 325.14M | 306.91M | 265.20M | -396.24K | -12.27M | 43.14M | -1.90M | 10.01M | 23.29M | 14.98M | 12.71M | 4.64M | 11.08M | 2.22M | 2.13M | 501.83K |
| Operating Expenses | 1.72B | 856.79M | 946.66M | 934.57M | 895.82M | 792.05M | 828.87M | 499.32M | 136.10M | 137.99M | 116.14M | 108.06M | 84.55M | 53.08M | 53.87M | 30.99M | 26.57M |
| Cost & Expenses | 7.79B | 6.17B | 6.56B | 8.21B | 7.20B | 4.29B | 2.51B | 1.28B | 1.01B | 870.44M | 944.24M | 974.32M | 852.00M | 622.55M | 656.38M | 402.87M | 298.49M |
| Interest Income | -6.02M | 15.97M | 20.67M | 37.73M | 20.95M | 55.59M | 35.08M | 4.43M | 890.50K | 0.00 | 7.51M | 7.29M | 3.55M | 199.65K | 282.70K | 0.00 | 0.00 |
| Interest Expense | 283.70M | 357.91M | 1.14B | 560.91M | 255.05M | 90.53M | 176.26M | 18.01M | 22.77M | 13.70M | 10.47M | 4.37M | 7.79M | 9.24M | 11.35M | 4.58M | 1.61M |
| Depreciation & Amortization | 350.08M | 403.31M | 338.94M | 266.08M | 201.06M | 180.94M | 135.26M | 43.18M | 37.30M | 31.19M | 23.97M | 20.95M | 16.05M | 13.41M | 10.03M | 6.29M | 3.02M |
| EBITDA | 693.03M | 1.62B | 1.27B | 1.52B | 1.49B | 1.38B | 1.47B | 773.52M | 98.29M | 77.66M | 111.79M | 112.70M | 85.33M | 80.13M | 87.63M | 46.80M | 21.07M |
| EBITDA Ratio | 8.55% | 21.18% | 18.29% | 16.34% | 17.60% | 25.78% | 39.50% | 38.23% | 9.27% | 8.68% | 11.07% | 10.74% | 9.33% | 11.82% | 11.97% | 10.51% | 6.60% |
| Operating Income | 342.95M | 1.22B | 930.64M | 1.26B | 609.94M | 1.08B | 1.12B | 689.86M | 24.85M | 6.65M | 59.65M | 72.67M | 54.99M | 44.84M | 54.56M | 40.20M | 18.05M |
| Operating Income Ratio | 4.23% | 15.92% | 13.41% | 13.48% | 7.22% | 20.19% | 30.04% | 34.09% | 2.34% | 0.74% | 5.91% | 6.93% | 6.02% | 6.61% | 7.45% | 9.03% | 5.66% |
| Total Other Income/Expenses | -2.00B | -1.59B | -2.05B | -781.24M | -396.24K | -12.27M | 15.62M | -2.60M | 9.90M | 23.05M | 14.11M | 12.71M | 4.58M | 11.08M | 2.22M | 2.13M | 501.83K |
| Income Before Tax | -1.66B | -367.96M | -1.12B | 476.57M | 609.54M | 1.07B | 1.13B | 687.25M | 34.76M | 29.70M | 73.76M | 85.38M | 59.57M | 55.92M | 56.77M | 42.34M | 18.56M |
| Income Before Tax Ratio | -20.46% | -4.80% | -16.11% | 5.11% | 7.22% | 19.96% | 30.46% | 33.97% | 3.28% | 3.32% | 7.31% | 8.14% | 6.52% | 8.25% | 7.76% | 9.51% | 5.81% |
| Income Tax Expense | -603.86M | 291.72M | -45.49M | 97.96M | 183.61M | 170.72M | 172.20M | 118.97M | 4.71M | 5.64M | 11.00M | 13.25M | 8.54M | 9.18M | 11.06M | 6.78M | 3.99M |
| Net Income | -1.05B | -659.67M | -1.07B | 354.66M | 404.19M | 892.63M | 953.64M | 568.29M | 28.40M | 26.89M | 61.60M | 62.57M | 39.20M | 40.26M | 39.15M | 33.16M | 14.43M |
| Net Income Ratio | -13.01% | -8.61% | -15.46% | 3.80% | 4.79% | 16.63% | 25.61% | 28.09% | 2.68% | 3.01% | 6.10% | 5.97% | 4.29% | 5.94% | 5.35% | 7.45% | 4.52% |
| EPS | -0.66 | -0.43 | -0.70 | 0.16 | 0.26 | 0.58 | 0.65 | 0.62 | 0.53 | 0.08 | 0.18 | 0.18 | 0.13 | 0.16 | 0.15 | 0.15 | 0.11 |
| EPS Diluted | -0.66 | -0.43 | -0.70 | 0.16 | 0.26 | 0.58 | 0.65 | 0.62 | 0.53 | 0.08 | 0.18 | 0.18 | 0.13 | 0.16 | 0.15 | 0.15 | 0.11 |
| Weighted Avg Shares Out | 1.60B | 1.52B | 1.53B | 1.53B | 1.53B | 1.53B | 1.46B | 905.82M | 905.88M | 336.09M | 342.22M | 347.64M | 309.46M | 258.79M | 259.92M | 227.65M | 135.95M |
| Weighted Avg Shares Out (Dil) | 1.60B | 1.52B | 1.53B | 1.53B | 1.53B | 1.53B | 1.46B | 905.82M | 905.88M | 336.09M | 342.22M | 347.64M | 309.46M | 258.79M | 259.92M | 227.65M | 135.95M |
Source: https://incomestatements.info
Category: Stock Reports